Table 3:

Measures of association between First Nation status (reference general population) and each of the study outcomes^*

Outcomes	Full-group analysis n = 696		Stratified analysis

			Crohn disease n = 342		Ulcerative colitis n = 354

	Unadjusted HR (95% CI)	Adjusted HR (95% CI)^†	Unadjusted HR (95% CI)	Adjusted HR (95% CI)^‡	Unadjusted HR (95% CI)	Adjusted HR (95% CI)^§
Outpatient gastroenterologist visit	1.10 (0.88–1.37)	1.13 (0.90–1.41)	0.95 (0.65–1.39)	0.99 (0.67–1.45)	1.22 (0.92–1.61)	1.20 (0.91–1.59)

Colonoscopy	1.25 (1.01–1.54)^¶	1.14 (0.92–1.41)	1.19 (0.83–1.72)	1.20 (0.83–1.73)	1.11 (0.86–1.45)	1.11 (0.85–1.44)

Prescription claim for IBD	0.58 (0.47–0.73)^¶	0.52 (0.41–0.65)^¶	0.53 (0.35–0.78)^¶	0.51 (0.34–0.76)^¶	0.52 (0.39–0.68)^¶	0.51 (0.39–0.68)^¶

Prescription claim of a biologic	0.58 (0.34–0.99)^¶	0.65 (0.38–1.11)	0.67 (0.33–1.38)	0.67 (0.32–1.37)	0.61 (0.28–1.35)	0.62 (0.28–1.36)

Prescription claim of an IM	0.70 (0.48–1.01)	0.79 (0.55–1.15)	0.68 (0.40–1.15)	0.69 (0.40–1.17)	0.93 (0.55–1.57)	0.93 (0.55–1.58)

Prescription claim of a 5-ASA	0.68 (0.54–0.85)^¶	0.56 (0.45–0.71)^¶	0.60 (0.39–0.92)^¶	0.56 (0.36–0.86)^¶	0.54 (0.41–0.72)^¶	0.54 (0.41–0.72)^¶

IBD-specific hospitalization	1.24 (0.94–1.63)	1.33 (1.01–1.75)^¶	1.55 (1.04–2.30)^¶	1.50 (1.00–2.23)	1.18 (0.80–1.72)	1.17 (0.80–1.71)

IBD-related hospitalization	1.45 (1.12–1.87)^¶	1.55 (1.20–2.01)^¶	1.74 (1.19–2.54)^¶	1.68 (1.14–2.46)^¶	1.42 (1.00–2.01)	1.41 (1.00–2.00)

Surgery for IBD	1.13 (0.79–1.62)	1.14 (0.80–1.64)	0.95 (0.52–1.72)	0.93 (0.51–1.70)	1.32 (0.84–2.07)	1.30 (0.83–2.05)

Note: 5-ASA = 5-aminosalicylic acid, CI = confidence interval, HR = hazard ratio, IBD = inflammatory bowel disease, IM = immune modulator.
↵* Unless stated otherwise.
↵† Models adjusted by rural or urban status, and diagnosis type (n = 691).
↵‡ Crohn disease group, models adjusted by rural/urban status (n = 339).
↵§ Ulcerative colitis group, models adjusted by rural/urban status (n = 352).
↵¶ Bold values denote significant results.